Viking Therapeutics to Present at Upcoming Life Science Industry Events

SAN DIEGO, Nov. 12, 2015 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver corporate presentations at two upcoming life science industry events. Details for these presentations are as follows:

• Stifel Healthcare Conference 2015 – webcast available
  Time/Date:  2:15 – 2:55 p.m. ET on Tuesday, November 17, 2015
  Location:  The New York Palace Hotel, New York City
• Ligand Pharmaceuticals Analyst Day  – webcast available
  Time/Date:  10:00 – 11:30 a.m. ET on Wednesday, November 18, 2015
  Location:  Le Parker Meridien Hotel, New York City

To access the live webcast of Viking's presentation at the Stifel conference, please visit "Webcasts & Presentations" within the News & Events section of Viking's Investors page at www.vikingtherapeutics.com. Additionally, a replay of the webcast will be available on the Viking website following the conference.

The Ligand analyst day will be webcast live and can be accessed at www.ligand.com.  A replay of this webcast will be available for 90 days following the event.

About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders.  The company's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives.  Viking has exclusive worldwide rights to a portfolio of five therapeutic programs in clinical trials or preclinical studies, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated.  The company's clinical programs include VK5211, an orally available, non-steroidal SARM, in Phase 2 development for the treatment and prevention of lean body mass loss in patients who have undergone hip fracture surgery, VK2809, a small molecule thyroid beta agonist entering Phase 2 development for hypercholesterolemia and fatty liver disease, and VK0612, a first-in-class, orally available drug candidate in Phase 2 development for type 2 diabetes.  Viking is also developing novel and selective agonists of the thyroid beta receptor for adrenoleukodystrophy, as well as two earlier-stage programs targeting metabolic diseases and anemia.

Learn more at: www.vikingtherapeutics.com.

Forward Looking Statements
This press release contains forward-looking statements regarding Viking Therapeutics, including statements about Viking's research and development activities. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: risks associated with the success, cost and timing of Viking's product candidate development activities and clinical trials; and risks regarding regulatory requirements, among others. These forward-looking statements speak only as of the date hereof.  Viking disclaims any obligation to update these forward-looking statements.

SOURCE Viking Therapeutics, Inc.